Clinical evidence of intestinal absorption of Gastrografin.
Experimental evidence suggests that Gastrografin in the neonatal gastrointestinal tract leads to hypertonic dehydration by two mechanisms: loss of water from the circulating blood volume, and absorption of osmolarly active substances across intact, normal mucosa of the gastrointestinal tract. Clinical documentation of absorption of Gastrografin is presented. Renal excretion of contrast material was seen following its use in the treatment of meconium ileus.
D003973:Diatrizoate / Q000031:analogs & derivatives* / Q000378:metabolism*; D003974:Diatrizoate Meglumine / Q000378:metabolism; D006801:Humans; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000000981:diagnostic imaging; D007408:Intestinal Absorption; D007415:Intestinal Obstruction / Q000000981:diagnostic imaging; D007668:Kidney / Q000000981:diagnostic imaging; D008470:Meconium; D011860:Radiography, Abdominal; D001743:Urinary Bladder / Q000000981:diagnostic imaging
D003973:Diatrizoate; D003974:Diatrizoate Meglumine